Previous close | 3.0000 |
Open | 3.0000 |
Bid | 0.0000 |
Ask | 4.3000 |
Strike | 1,105.00 |
Expiry date | 2024-07-05 |
Day's range | 3.0000 - 3.0000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) or on a combination of LABA and LAMA if ICS is not appropriate. Sanofi SA (NASDAQ
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.